In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leadership

Set Alert for Leadership

Giant LEAPS For Mankind: Bayer's Malik On Breaking The Mold In R&D

As new scientific breakthroughs are shaking the foundations of pharma and biotech R&D, In Vivo sat down with Bayer's Kemal Malik to hear how the German big pharma is responding to the challenges with its ground-breaking LEAPS program.

Financing Regenerative Medicine Research & Development
Advertisement

Latest From Leadership

Back To The Future: Novo’s Sørensen Reflects On CEO Years And Tasks Ahead For Industry

Lars Rebien Sørensen scrutinizes the pharmaceutical industry and shares with In Vivo his vision for the future of the Novo Nordisk Foundation. With 16 years as CEO of Novo Nordisk under his belt, as well as many more years in leadership roles at the Danish company, Sørensen reflects on the past and gives his predictions for the future of the innovative drug development sector.

Leadership Strategy

Bayer’s US Playbook: The Smart Way To Top-Line Growth

The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.

Leadership Growth

Execs On The Move, June 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership Appointments

The Value Of Being Decisive On Strategic Needs – Through One Pharma CEO's Lens

After a promising research program failed to deliver, London-listed Circassia changed from being an R&D-based allergy company to one focused on commercial respiratory therapies. Rapid decision-making averted a crisis and earned the company a US deal and equity partnership with AstraZeneca. As an exercise in Plan B readiness, it's surely up there with the best.

Leadership Business Strategies

New Novartis CDO Bodson Outlines Digital Health Ambitions

Bertrand Bodson, the new chief digital officer for Novartis, reveals how he sees digital health underpinning the Swiss major’s future. Efforts at the company have already delivered a 10 to 15% reduction in patient enrollment times in pilot trials.

Clinical Trials Digital Health

Execs On The Move, May 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership Appointments
See All
UsernamePublicRestriction

Register